Design of Anti- and Pro-aggregation Variants to Assess the Effects of Methionine Oxidation in Human Prion Protein

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2009 May 7

PMID 19416900

Citations 34

Authors

Christina Wolschner

Armin Giese

Hans A Kretzschmar

Robert Huber

Luis Moroder

Nediljko Budisa

Affiliations

Soon will be listed here.

Abstract

Prion disease is characterized by the alpha-->beta structural conversion of the cellular prion protein (PrP(C)) into the misfolded and aggregated "scrapie" (PrP(Sc)) isoform. It has been speculated that methionine (Met) oxidation in PrP(C) may have a special role in this process, but has not been detailed and assigned individually to the 9 Met residues of full-length, recombinant human PrP(C) [rhPrP(C)(23-231)]. To better understand this oxidative event in PrP aggregation, the extent of periodate-induced Met oxidation was monitored by electrospray ionization-MS and correlated with aggregation propensity. Also, the Met residues were replaced with isosteric and chemically stable, nonoxidizable analogs, i.e., with the more hydrophobic norleucine (Nle) and the highly hydrophilic methoxinine (Mox). The Nle-rhPrP(C) variant is an alpha-helix rich protein (like Met-rhPrP(C)) resistant to oxidation that lacks the in vitro aggregation properties of the parent protein. Conversely, the Mox-rhPrP(C) variant is a beta-sheet rich protein that features strong proaggregation behavior. In contrast to the parent Met-rhPrP(C), the Nle/Mox-containing variants are not sensitive to periodate-induced in vitro aggregation. The experimental results fully support a direct correlation of the alpha-->beta secondary structure conversion in rhPrP(C) with the conformational preferences of Met/Nle/Mox residues. Accordingly, sporadic prion and other neurodegenerative diseases, as well as various aging processes, might also be caused by oxidative stress leading to Met oxidation.

Citing Articles

Reaching New Heights in Genetic Code Manipulation with High Throughput Screening.

Lino B, Williams S, Castor M, Van Deventer J Chem Rev. 2024; 124(21):12145-12175.

PMID: 39418482 PMC: 11879460. DOI: 10.1021/acs.chemrev.4c00329.

Methionine Sulfoxide Reductases Suppress the Formation of the [] Prion and Protein Aggregation in Yeast.

Schepers J, Carter Z, Kritsiligkou P, Grant C Antioxidants (Basel). 2023; 12(2).

PMID: 36829961 PMC: 9952077. DOI: 10.3390/antiox12020401.

Oxidative Stress in Age-Related Neurodegenerative Diseases: An Overview of Recent Tools and Findings.

Korovesis D, Rubio-Tomas T, Tavernarakis N Antioxidants (Basel). 2023; 12(1).

PMID: 36670993 PMC: 9854433. DOI: 10.3390/antiox12010131.

Halogenation of tyrosine perturbs large-scale protein self-organization.

Sun H, Jia H, Kendall O, Dragelj J, Kubyshkin V, Baumann T Nat Commun. 2022; 13(1):4843.

PMID: 35977922 PMC: 9385671. DOI: 10.1038/s41467-022-32535-2.

Residue-Specific Incorporation of the Non-Canonical Amino Acid Norleucine Improves Lipase Activity on Synthetic Polyesters.

Haernvall K, Fladischer P, Schoeffmann H, Zitzenbacher S, Pavkov-Keller T, Gruber K Front Bioeng Biotechnol. 2022; 10:769830.

PMID: 35155387 PMC: 8826565. DOI: 10.3389/fbioe.2022.769830.

References

Wong B, Wang H, Brown D, Jones I . Selective oxidation of methionine residues in prion proteins. Biochem Biophys Res Commun. 1999; 259(2):352-5. DOI: 10.1006/bbrc.1999.0802. View

Bolton D, McKinley M, Prusiner S . Identification of a protein that purifies with the scrapie prion. Science. 1982; 218(4579):1309-11. DOI: 10.1126/science.6815801. View

Moskovitz J, Williams W, Requena J, Berlett B, Stadtman E . Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci U S A. 2001; 98(23):12920-5. PMC: 60800. DOI: 10.1073/pnas.231472998. View

Minor Jr D, Kim P . Measurement of the beta-sheet-forming propensities of amino acids. Nature. 1994; 367(6464):660-3. DOI: 10.1038/367660a0. View

Breydo L, Bocharova O, Makarava N, Salnikov V, Anderson M, Baskakov I . Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation. Biochemistry. 2005; 44(47):15534-43. DOI: 10.1021/bi051369+. View

Prusiner S . Prion diseases and the BSE crisis. Science. 1997; 278(5336):245-51. DOI: 10.1126/science.278.5336.245. View

Bieschke J, Giese A, Schulz-Schaeffer W, Zerr I, Poser S, Eigen M . Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci U S A. 2000; 97(10):5468-73. PMC: 25852. DOI: 10.1073/pnas.97.10.5468. View

Chiti F, Dobson C . Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006; 75:333-66. DOI: 10.1146/annurev.biochem.75.101304.123901. View

Budisa N . Prolegomena to future experimental efforts on genetic code engineering by expanding its amino acid repertoire. Angew Chem Int Ed Engl. 2004; 43(47):6426-63. DOI: 10.1002/anie.200300646. View

10.

Dayhoff M, Barker W, Hunt L . Establishing homologies in protein sequences. Methods Enzymol. 1983; 91:524-45. DOI: 10.1016/s0076-6879(83)91049-2. View

11.

Lysek D, Schorn C, Nivon L, Esteve-Moya V, Christen B, Calzolai L . Prion protein NMR structures of cats, dogs, pigs, and sheep. Proc Natl Acad Sci U S A. 2005; 102(3):640-5. PMC: 545531. DOI: 10.1073/pnas.0408937102. View

12.

Knowles J . THE ROLE OF METHIONINE IN ALPHA-CHYMOTRYPSIN-CATALYSED REACTIONS. Biochem J. 1965; 95:180-90. PMC: 1215192. DOI: 10.1042/bj0950180. View

13.

DeMarco M, Daggett V . Characterization of cell-surface prion protein relative to its recombinant analogue: insights from molecular dynamics simulations of diglycosylated, membrane-bound human prion protein. J Neurochem. 2009; 109(1):60-73. PMC: 2674387. DOI: 10.1111/j.1471-4159.2009.05892.x. View

14.

Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes M, Langeveld J . Methionine sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry. 2008; 47(34):8866-73. DOI: 10.1021/bi800801f. View

15.

Moskovitz J, Weissbach H, Brot N . Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc Natl Acad Sci U S A. 1996; 93(5):2095-9. PMC: 39915. DOI: 10.1073/pnas.93.5.2095. View

16.

Winklhofer K, Heske J, Heller U, Reintjes A, Muranyi W, Moarefi I . Determinants of the in vivo folding of the prion protein. A bipartite function of helix 1 in folding and aggregation. J Biol Chem. 2003; 278(17):14961-70. DOI: 10.1074/jbc.M209942200. View

17.

Budisa N, Huber R, Golbik R, Minks C, Weyher E, Moroder L . Atomic mutations in annexin V--thermodynamic studies of isomorphous protein variants. Eur J Biochem. 1998; 253(1):1-9. DOI: 10.1046/j.1432-1327.1998.2530001.x. View

18.

Ronga L, Palladino P, Saviano G, Tancredi T, Benedetti E, Ragone R . Structural characterization of a neurotoxic threonine-rich peptide corresponding to the human prion protein alpha 2-helical 180-195 segment, and comparison with full-length alpha 2-helix-derived peptides. J Pept Sci. 2008; 14(10):1096-102. DOI: 10.1002/psc.1046. View

19.

Petropoulos I, Friguet B . Maintenance of proteins and aging: the role of oxidized protein repair. Free Radic Res. 2006; 40(12):1269-76. DOI: 10.1080/10715760600917144. View

20.

Rubini M, Lepthien S, Golbik R, Budisa N . Aminotryptophan-containing barstar: structure--function tradeoff in protein design and engineering with an expanded genetic code. Biochim Biophys Acta. 2006; 1764(7):1147-58. DOI: 10.1016/j.bbapap.2006.04.012. View